Table 1

Baseline demographics and disease characteristics

N = 27
Age (y), median (min, max) 78.0 (64, 92) 
Age distribution, n (%)  
 <65 y 2 (7) 
 ≥65 and ≤74 y 8 (30) 
 ≥75 and ≤84 y 12 (44) 
 ≥85 y 5 (19) 
Gender, male, n (%) 14 (52) 
ECOG performance status, n (%)  
 Grade 0/1 21 (78) 
 Grade 2/3 6 (22) 
Karnofsky performance status, median (min, max) 90 (60, 100) 
Histologic subtype of HL  
 Nodular sclerosis 12 (44) 
 Mixed cellularity 5 (19) 
 Lymphocyte-rich classical HL 4 (15) 
 Lymphocyte-depleted classical HL 1 (4) 
 Classical HL NOS 4 (15) 
 Other (NLPHL)* 1 (4) 
Stage at diagnosis, n (%)  
  Early stage I/II 10 (37) 
  Late stage III/IV 17 (63) 
Percent CD30+ malignant cells, median (min, max) 90 (20, 100) 
B symptoms, n (%) 6 (22) 
Bulky disease, n (%) 6 (22) 
Extra-nodal involvement, n (%) 14 (52) 
Renal impairment category, n (%)  
 Unimpaired (CrCl >80 mL/min) 8 (30) 
 Mild (CrCl >50 to ≤80 mL/min) 7 (26) 
 Moderate (CrCl ≥30 to ≤50 mL/min) 12 (44) 
Cardiac ejection fraction, %, median (min, max) 65 (49, 74) 
N = 27
Age (y), median (min, max) 78.0 (64, 92) 
Age distribution, n (%)  
 <65 y 2 (7) 
 ≥65 and ≤74 y 8 (30) 
 ≥75 and ≤84 y 12 (44) 
 ≥85 y 5 (19) 
Gender, male, n (%) 14 (52) 
ECOG performance status, n (%)  
 Grade 0/1 21 (78) 
 Grade 2/3 6 (22) 
Karnofsky performance status, median (min, max) 90 (60, 100) 
Histologic subtype of HL  
 Nodular sclerosis 12 (44) 
 Mixed cellularity 5 (19) 
 Lymphocyte-rich classical HL 4 (15) 
 Lymphocyte-depleted classical HL 1 (4) 
 Classical HL NOS 4 (15) 
 Other (NLPHL)* 1 (4) 
Stage at diagnosis, n (%)  
  Early stage I/II 10 (37) 
  Late stage III/IV 17 (63) 
Percent CD30+ malignant cells, median (min, max) 90 (20, 100) 
B symptoms, n (%) 6 (22) 
Bulky disease, n (%) 6 (22) 
Extra-nodal involvement, n (%) 14 (52) 
Renal impairment category, n (%)  
 Unimpaired (CrCl >80 mL/min) 8 (30) 
 Mild (CrCl >50 to ≤80 mL/min) 7 (26) 
 Moderate (CrCl ≥30 to ≤50 mL/min) 12 (44) 
Cardiac ejection fraction, %, median (min, max) 65 (49, 74) 

NOS, not otherwise specified.

*

One patient who received brentuximab vedotin was later determined to have NLPHL (protocol violation).

No patient had severe renal impairment (CrCl <30 mL/min).

Close Modal

or Create an Account

Close Modal
Close Modal